

Lung Cancer AUC evidence project – Evidence-based Guidelines Included in the Recommendation Matrix

Mean Guideline Scores and Scaled Scores across Domains of the AGREE II Instrument

AGREE II Domain	AGREE II Domain Topics	British Thoracic Society (Callister et al) 2015. Guidelines for the investigation and management of pulmonary nodules.	American College of Chest Physicians (Colt et al) 2013. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy.	American College of Radiology (Cox et al) 2020. ACR Appropriateness Criteria® Occupational Lung Diseases.	American College of Radiology (de Groot et al) 2019. ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer.	European Society for Medical Oncology (Dingemans et al) 2021. Small-cell lung cancer: Clinical practice guidelines for diagnosis, treatment and follow-up.	American College of Radiology (Sandler et al) 2022. ACR Appropriateness Criteria® Lung Cancer Screening.	National Comprehensive Cancer Network (Ettinger et al) 2023. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer.
Total Score EXCLUDING overall assessment score		122.5	113.5	105.5	107.5	95	112	125
Scaled Total Score Excluding overall assessment score		72%	66%	60%	61%	52%	64%	74%
Overall Assessment	Would you recommend this guideline for use in practice?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Overall Assessment Score	Rate the overall quality of the guideline (Scale of 1 to 7) NOTE: The overall assessment score is not included in the total score	5.5	5	4.5	4.5	4	5	5.5
Scope and Purpose	Domain Score	20	16	13	14	12	17	17
	Scaled Domain Score Percentage	94%	72%	56%	61%	50%	78%	78%
Stakeholder Involvement	Domain Score	17	15	12.5	13.5	11.5	12.5	14.5
	Scaled Domain Score Percentage	78%	67%	53%	58%	47%	53%	64%
Rigor of Development	Domain Score	45	38.5	42	39.5	32	41.5	44
	Scaled Domain Score Percentage	77%	64%	71%	66%	50%	70%	75%
Clarity and Presentation	Domain Score	17	17	16.5	18	14	19.5	18
	Scaled Domain Score Percentage	78%	78%	75%	83%	61%	92%	83%
Applicability	Domain Score	16.5	14.5	12.5	15.5	13.5	12	20
	Scaled Domain Score Percentage	52%	44%	33%	48%	40%	33%	67%
Editorial Independence	Domain Score	7	12.5	9.5	7	12	9.5	11.5
	Scaled Domain Score Percentage	42%	88%	63%	42%	83%	63%	79%

*Mean guidelines scores across domains of the AGREE II instrument. Each question was rated on a Likert scale with a maximum of 7 points. The scores are averaged for each of the 2 reviewers. The scaled domain score is calculated as follows: (obtained score – minimum possible score) ÷ (maximum possible score – minimum possible score)

Mean Guideline Scores and Scaled Scores across Domains of the AGREE II Instrument

AGREE II Domain	AGREE II Domain Topics	National Comprehensive Cancer Network (Ganti et al) 2023. NCCN clinical practice guidelines in oncology: Small cell lung cancer.	American College of Chest Physicians (Gould et al) 2013. Evaluation of individuals with pulmonary nodules: When is it lung cancer?	Society of Nuclear Medicine and Molecular Imaging (Jadvar et al) 2017. Appropriate use criteria for ¹⁸ F-FDG PET/CT in restaging and treatment response assessment of malignant disease.	American College of Chest Physicians (Jett et al) 2013. Treatment of small cell lung cancer.	American College of Radiology (Martin et al) 2023. ACR Appropriateness Criteria® radiographically detected solitary pulmonary nodule.	American College of Chest Physicians (Kozower et al) 2013. Special treatment issues in non-small cell lung cancer.
Total Score EXCLUDING overall assessment score		126	119.5	114	113	108	113
Scaled Total Score Excluding overall assessment score		75%	70%	66%	65%	62%	65%
Overall Assessment	Would you recommend this guideline for use in practice?	Yes	Yes	Yes	Yes	Yes	Yes
Overall Assessment Score	Rate the overall quality of the guideline (Scale of 1 to 7) NOTE: The overall assessment score is not included in the total score	5.5	5	5	5	4.5	5
Scope and Purpose	Domain Score	17	18	18.5	15	12	16.5
	Scaled Domain Score Percentage	78%	83%	86%	67%	50%	75%
Stakeholder Involvement	Domain Score	15.5	15.5	15	12	12.5	13.5
	Scaled Domain Score Percentage	69%	69%	67%	50%	53%	58%
Rigor of Development	Domain Score	44.5	40	40	40	42.5	39
	Scaled Domain Score Percentage	76%	67%	67%	67%	72%	65%
Clarity and Presentation	Domain Score	18	18	13.5	17.5	19.5	17.5
	Scaled Domain Score Percentage	83%	83%	58%	81%	92%	81%
Applicability	Domain Score	19.5	15.5	18	14.5	12	13.5
	Scaled Domain Score Percentage	65%	48%	58%	44%	33%	40%
Editorial Independence	Domain Score	11.5	11.5	9	12.5	9.5	13
	Scaled Domain Score Percentage	79%	79%	58%	88%	63%	92%

*Mean guidelines scores across domains of the AGREE II instrument. Each question was rated on a Likert scale with a maximum of 7 points. The scores are averaged for each of the 2 reviewers. The scaled domain score is calculated as follows: (obtained score – minimum possible score) ÷ (maximum possible score – minimum possible score)

Mean Guideline Scores and Scaled Scores across Domains of the AGREE II Instrument

AGREE II Domain	AGREE II Domain Topics	Fleischner Society (MacMahon et al) 2017. Guidelines for management of incidental pulmonary nodules detected on CT images.	American College of Chest Physicians (Mazzone et al) 2021. Screening for lung cancer: CHEST guidelines and expert panel report.	National Institute for Health and Care Excellence (NICE) 2019. Lung cancer: Diagnosis and management.	American College of Radiology (Olsen et al) 2020. ACR Appropriateness Criteria® Hemoptysis.	American College of Chest Physicians (Ost et al) 2013. Clinical and organizational factors in the initial evaluation of patients with lung cancer.	European Society for Medical Oncology (Planchard et al) 2018). Metastatic non-small cell lung cancer: Clinical practice guidelines for diagnosis, treatment and follow-up.
Total Score EXCLUDING overall assessment score		102.5	121	145	109	110	94
Scaled Total Score Excluding overall assessment score		58%	71%	88%	62%	63%	51%
Overall Assessment	Would you recommend this guideline for use in practice?	Yes	Yes	Yes	Yes	Yes	Yes
Overall Assessment Score	Rate the overall quality of the guideline (Scale of 1 to 7) NOTE: The overall assessment score is not included in the total score	4.5	5.5	6.5	4.5	5	4
Scope and Purpose	Domain Score	16.5	17	15.5	15	17.5	12
	Scaled Domain Score Percentage	75%	78%	69%	67%	81%	50%
Stakeholder Involvement	Domain Score	15.5	17	17	12.5	14.5	12
	Scaled Domain Score Percentage	69%	78%	78%	53%	64%	50%
Rigor of Development	Domain Score	32.5	42.5	52.5	42.5	38.5	32
	Scaled Domain Score Percentage	51%	72%	93%	72%	64%	50%
Clarity and Presentation	Domain Score	15.5	16	21	17.5	13.5	13
	Scaled Domain Score Percentage	69%	72%	100%	81%	58%	56%
Applicability	Domain Score	13.5	15.5	26.5	12	13	13
	Scaled Domain Score Percentage	40%	48%	94%	33%	38%	38%
Editorial Independence	Domain Score	9	13	12.5	9.5	13	12
	Scaled Domain Score Percentage	58%	92%	88%	63%	92%	83%

*Mean guidelines scores across domains of the AGREE II instrument. Each question was rated on a Likert scale with a maximum of 7 points. The scores are averaged for each of the 2 reviewers. The scaled domain score is calculated as follows: (obtained score – minimum possible score) ÷ (maximum possible score – minimum possible score)

Mean Guideline Scores and Scaled Scores across Domains of the AGREE II Instrument

AGREE II Domain	AGREE II Domain Topics	American Society of Clinical Oncology (Schneider et al) 2019. Lung cancer surveillance after definitive curative-intent therapy.	American College of Chest Physicians (Silvestri et al) 2013. Methods for staging non-small cell lung cancer.	US Preventive Service Task Force (Krist et al) 2021. Screening for lung cancer: US Preventive Services Task Force recommendation statement.	National Comprehensive Cancer Network (Wood et al) 2023. Lung cancer screening.	American Cancer Society (Wender et al) 2013. Lung cancer screening guidelines.
Total Score EXCLUDING overall assessment score		130.5	115.5	117	128.5	110.5
Scaled Total Score Excluding overall assessment score		78%	67%	68%	76%	63%
Overall Assessment	Would you recommend this guideline for use in practice?	Yes	Yes	Yes	Yes	Yes
Overall Assessment Score	Rate the overall quality of the guideline (Scale of 1 to 7) NOTE: The overall assessment score is not included in the total score	5.5	5	5	5.5	5
Scope and Purpose	Domain Score	18	17.5	20.5	19	19.5
	Scaled Domain Score Percentage	83%	81%	97%	89%	92%
Stakeholder Involvement	Domain Score	17.5	15	12.5	14.5	14
	Scaled Domain Score Percentage	81%	67%	53%	64%	61%
Rigor of Development	Domain Score	44	39.5	41	46	39.5
	Scaled Domain Score Percentage	75%	66%	69%	79%	66%
Clarity and Presentation	Domain Score	17.5	15.5	17.5	17.5	13
	Scaled Domain Score Percentage	81%	69%	81%	81%	56%
Applicability	Domain Score	21.5	15	11.5	20	12
	Scaled Domain Score Percentage	73%	46%	31%	67%	33%
Editorial Independence	Domain Score	12	13	14	11.5	12.5
	Scaled Domain Score Percentage	83%	92%	100%	79%	88%

*Mean guidelines scores across domains of the AGREE II instrument. Each question was rated on a Likert scale with a maximum of 7 points. The scores are averaged for each of the 2 reviewers. The scaled domain score is calculated as follows: (obtained score – minimum possible score) ÷ (maximum possible score – minimum possible score)